Aurealis Therapeutics raises $10 Million in an oversubscribed Series A financing to accelerate Phase 2 clinical studies in chronic wounds and preclinical development in oncology with its first-in-class technology platform
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs. The funds will be primarily used to […]
